Q: I have owned Theratechnologies since 2018 and watched this stock fall since I purchased it. The stock has been rising the last few weeks and was up 23% on Friday. I couldn't find any exciting press releases that would explain the increase. Do you know of any reason for the recent increase?
The 5 analysts listed on Qtrade have a price target of anywhere from $5.50-$12.04. How much faith can we put in the price targets of analysts?
I was quite excited that it was up to $3.03 but just noticed there was a 4 for 1 stock split in August 2023 so my 700 shares are now only 175 shares. So rather than being down 60% I am actually down 90%. Yikes, I better not tell my wife about this trade!
My holdings in TH are only worth $530 now. Should I sell this loser now or is it worth waiting until the annual report (November year end) comes out?
The 5 analysts listed on Qtrade have a price target of anywhere from $5.50-$12.04. How much faith can we put in the price targets of analysts?
I was quite excited that it was up to $3.03 but just noticed there was a 4 for 1 stock split in August 2023 so my 700 shares are now only 175 shares. So rather than being down 60% I am actually down 90%. Yikes, I better not tell my wife about this trade!
My holdings in TH are only worth $530 now. Should I sell this loser now or is it worth waiting until the annual report (November year end) comes out?
5i Research Answer:
There was no specific news on Friday, but on Jan. 02 TH submitted to the FDA a supplemental bilogics licensing application (sBLA) for an intramuscular method of delivering Trogarzo (a combination HIV treatment). This gives patients more options vs IV treatment. We do not put much faith in analysts' price projections. Case in point: Research Capital in 2018 had a target price on TH of $78.00. Its high price that year was $58. The stock has moved up 42% this year, but the company has not created any long term shareholder value, it is small and risk, it has debt, and continues to lose money. We would be fine letting this one go after the big move this year already.